A citation-based method for searching scientific literature

Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
Times Cited: 253







List of shared articles



Times cited


Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Rumyana Dimova, Tsvetalina Tankova. Horm Metab Res 2021
0


Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12

An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
Lakshini Y Herat, Vance B Matthews, Aaron L Magno, Marcio G Kiuchi, Revathy Carnagarin, Markus P Schlaich. Expert Opin Pharmacother 2020
2

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Ona Kinduryte Schorling, Douglas Clark, Isabella Zwiener, Stefan Kaspers, Jisoo Lee, Hristo Iliev. Adv Ther 2020
2

Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials.
Adriana Sánchez-García, Mario Simental-Mendía, Juan Manuel Millán-Alanís, Luis E Simental-Mendía. Pharmacol Res 2020
3

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.
Daisuke Yabe, Atsutaka Yasui, Linong Ji, Moon-Kyu Lee, Ronald Ching Wan Ma, Tien-Jyun Chang, Tomoo Okamura, Cordula Zeller, Stefan Kaspers, Jisoo Lee,[...]. J Diabetes Investig 2019
9


Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Tadashi Toyama, Brendon L Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J Jardine, Hiddo L Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada,[...]. Diabetes Obes Metab 2019
63

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen,[...]. BMJ Open 2019
53

Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Chaojie Feng, Minxiang Wu, Zhengyue Chen, Xiongwei Yu, Zhenyu Nie, Yu Zhao, Beiyan Bao. Int Urol Nephrol 2019
5


Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang, Ben Wang, Jun Liang. Medicine (Baltimore) 2019
20

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int 2018
76